

Integrative Therapeutics for Antimicrobial Resistance and Autoimmune Disease: Evidence and Pathways

Nishant Shukla*

Abstract

Background: Antimicrobial resistance (AMR) is accelerating globally, while autoimmune diseases and adverse drug reactions (ADRs) continue to rise. Ayurveda offers immunomodulatory, antimicrobial, and detoxification-oriented interventions that may complement biomedical strategies. **Objective:** To propose a hypothesis-driven integrative model combining Ayurvedic phytotherapy, panchakarma detoxification, and personalized dosha-based care with evidence-based medical management to mitigate AMR emergence, modulate autoimmunity, and reduce ADR incidence. **Methods:** A synthesis of mechanistic literature on Ayurvedic herbs with antimicrobial or immune-modulating properties, alongside reviews of alternative AMR therapeutics and integrative autoimmune care. Proposed trial designs include randomized add-on studies stratified by immune phenotype, with outcomes such as microbial clearance, resistance gene dynamics, autoantibody titers, and ADR frequency. **Results:** Evidence suggests that non-traditional therapeutics – including botanicals, peptides, probiotics, and immune-modulating agents – can complement antimicrobial strategies and address limitations of conventional one-drug–one-target approaches. Ayurvedic herbs and formulations demonstrate antimicrobial and immunomodulatory effects in preclinical and clinical studies, while integrative autoimmune protocols show promising safety signals. **Conclusion:** A rigorously standardized integrative framework combining Ayurveda with modern diagnostics and stewardship warrants clinical trials to evaluate its potential to reduce antibiotic exposure, slow resistance selection, and modulate autoimmune pathways.

Keywords: Integrative medicine, Ayurveda, antimicrobial resistance, autoimmunity, adverse drug reactions, phytotherapy, drug resistance

INTRODUCTION

Antimicrobial resistance (AMR) is one of the most urgent global health threats. Resistance is rising across multiple pathogens, and projections indicate that several frontline antibiotics may lose efficacy within the next decade. Conventional antimicrobial development is limited by slow pipelines, rapid resistance evolution, and the inadequacy of single-target drug strategies [1–3].

*Author for Correspondence

Nishant Shukla

E-mail: nishantvd@rediffmail.com

Professor and Ex. Head of Kayachikitsa, Department of Kayachikitsa, Shree Gulabkunverba Ayurved Mahavidyalaya (SGAM) (Affiliated to Gujarat Ayurved University (GAU)), Jamnagar, Gujarat, India

Received Date: February 22, 2026

Accepted Date: June 26, 2026

Published Date: August 4, 2026

Citation: Nishant Shukla Integrative Therapeutics for Antimicrobial Resistance and Autoimmune Disease: Evidence and Pathways. Research & Reviews: A Journal of Immunology. 2026; 16(2): 25–30p.

Autoimmune diseases are simultaneously increasing worldwide, driven by genetic, environmental, and microbiome-related factors. Long-term immunosuppressive therapy often leads to ADRs, infections, and reduced quality of life [4–6].

Ayurveda provides a holistic healthcare paradigm, focusing on maintaining “ojas” or immune balance, detoxifying body through “shodhana therapies”, and personalised healthcare based on an individual’s Prakriti (constitutional type) [7–10].

Numerous Ayurvedic botanicals – such as Guduchi, Ashwagandha, Neem, Turmeric, and Guggulu – have shown antimicrobial, anti-inflammatory, antioxidant, and immunomodulatory activities in pre-clinical/clinical studies suggesting their role in boosting immunity, controlling inflammation, and fighting infections [11].

Incorporating evidence-based Ayurvedic interventions along with modern medicine strategies could offer a new and complementary approach towards overcoming antimicrobial resistance (AMR), managing autoimmune disorders, reducing ADRs, and enhancing overall health by delivering a personalised and holistic approach to care [12].

BACKGROUND

Antimicrobial Resistance: Limitations of Current Approaches

Modern antimicrobial strategies face challenges including:

- Rapid evolution of resistance genes.
- Limited pipeline of new antibiotics.
- Ineffectiveness of single-target therapies.
- Drug biotransformation reducing efficacy.

Recent reviews highlight the urgent need for alternative therapeutic approaches to combat the growing threat of antimicrobial resistance (AMR). Conventional antibiotics are becoming increasingly ineffective due to the rapid emergence and spread of resistant microorganisms, driving the search for innovative treatment strategies [13, 14]. Among the most promising alternatives are antimicrobial peptides, bacteriophage therapy, probiotics and RNA-based therapeutics. Antimicrobial peptides possess broad spectrum activity and can target pathogens using unique mechanisms reducing the chance of developing resistance. Bacteriophage therapy uses viruses which specifically infect and destroy bacterial cells while probiotics contribute to maintain the microbial balance preventing colonization by pathogens. RNA-based treatments offer opportunities to regulate the microbial genes and target the resistance mechanism. Collectively, they represent exciting tools for improving antimicrobial effectiveness for future AMR management [15, 16].

Autoimmune Disease Burden

Autoimmune disorders are chronic conditions characterized by an abnormal response by the immune system that leads to ongoing inflammation, damage, and dysfunction of the body's own cells, tissues, and organs. Common autoimmune diseases include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), and inflammatory bowel disease (IBD). With an increasing global prevalence of these disorders, there is considerable healthcare and socioeconomic burden and a negative impact on patient quality of life [17, 18]. Treatment relies mainly on corticosteroids, DMARDs/biologics, and other immunosuppressive agents, all of which have significant side effects including ADRs, risk of infection, organ toxicity, high costs, and variable efficacy. New advances in immunology offer hope through promising antigen-specific immunotherapies, immune tolerance induction, and modulation of regulatory immune cells that will be able to restore balance without requiring extensive suppression of the entire immune system [19, 20].

Ayurvedic Therapeutics: A Complementary Opportunity

Ayurvedic interventions relevant to AMR and autoimmunity include:

- *Phytotherapy*: Guduchi, Ashwagandha, Neem, Turmeric, Guggulu.
- *Panchakarma*: Detoxification therapies.
- *Rasayana Therapy*: Immune resilience.
- *Diet & Lifestyle*: Gut microbiota modulation.

METHODS

This conceptual framework synthesizes:

- Mechanistic studies on Ayurvedic herbs with antimicrobial or immune-modulating properties

- Reviews of alternative AMR therapeutics.
- Reports on integrative autoimmune management.
- Proposed clinical trial designs integrating Ayurveda with biomedical care.

Proposed Trial Designs

- Randomized Add-On Trials.
- Autoimmune Phenotype-Stratified Trials.
- Panchakarma-Integrated Protocols.

Outcome Measures

- Microbial clearance.
- Resistance gene dynamics.
- Autoantibody titers.
- ADR frequency.
- Quality of life.

RESULTS (SYNTHESIS OF EVIDENCE)

After evaluating the current evidence, it appears that some modern forms of alternative therapies may have tools for fighting antimicrobial resistance (AMR) and managing the symptoms of autoimmune diseases, as do some Ayurvedic therapies/medicines. Evidence has shown that alternative therapies for antimicrobials (for example, using antimicrobial peptides (AMPs), using bacteriophages, using probiotics, or using RNA-based therapies) appear promising in providing alternatives to current antibiotic therapies while reducing the opportunity for bacteria to develop resistance against clinically relevant antibiotics [21].

Preclinical and clinical research has also demonstrated that anti-microbial, anti-inflammatory, anti-oxidant, and/or immune modulatory activity can be found in many Ayurvedic plants/botanicals (for example, Neem, Turmeric, Guduchi, Ashwagandha). Activity of these botanical products can be beneficial in controlling the development of infection, regulating the immune response (to both infection and injury), and/or reducing chronic inflammation associated with autoimmune disorders [22].

Current advancements in the management of autoimmune disorders have focused on immune tolerance, antigen-specific therapies, and modifications to the microbiome (aka the “gut”). Similarly, Ayurvedic therapies/medicines may provide a beneficial adjunct to the above advances through creating balance in the immune system and improving the overall health of the patient. Examples of Ayurvedic therapies that may have application to these developments include the following: Rasayana therapy, Panchakarma, and/or lifestyle-based approaches [23].

In totality, the studies reviewed suggest that combining the use of Ayurveda with contemporary (i.e., evidence-based) biomedical strategies may reduce reliance on antibiotics, decrease the rate at which bacteria develop resistance to antibiotics, decrease the occurrence of adverse drug reactions, and improve patient outcomes. However, additional well-designed clinical trials will be required to establish the effectiveness, safety, and long-term benefits associated with these types of combined therapies.

Evidence for Non-Traditional Antimicrobial Approaches

Autoimmune disorders are chronic diseases that occur when your immune system mistakenly attacks your body’s own cells, tissues, and organs, resulting in ongoing inflammation, tissue damage, and impaired organ function. Common autoimmune diseases include rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease. The global incidence of these diseases has been growing rapidly, placing considerable strain on healthcare systems and impacting patients’ quality of life. Currently available treatments primarily involve corticosteroids, disease-modifying antirheumatic drugs (DMARDs), biologics, and other immunosuppressive agents to manage

disease activity and progression. But long-term use of these treatments can result in adverse drug reactions (ADRs), higher susceptibility to infection, organ toxicity, high treatment costs, and variable responses. New developments in immunology have uncovered innovative methods including antigen-specific immunotherapies, immune tolerance, and regulatory immune cell modulation to restore immune balance without extensive immunosuppression, potentially leading to safer and more effective treatments for autoimmune disorders [24].

Ayurvedic Botanicals with Antimicrobial and Immunomodulatory Activity

Preclinical and clinical studies report:

- Broad-spectrum antimicrobial effects (Neem, Turmeric).
- Immune-modulating effects (Guduchi, Ashwagandha).
- Anti-inflammatory and antioxidant properties.
- Potential to reduce pathogen load and modulate immune dysregulation.

Integrative Approaches in Autoimmune Disease

Recent reviews highlight key advancements in managing autoimmunity, including antigen-specific immunotherapies, immune tolerance, and novel nanomaterial drug delivery. Antigen-specific immunotherapies aim to selectively target harmful immune responses without affecting normal immunity. Immune tolerance studies focus on returning the body's ability to identify self-antigens and avoid misguided autoimmune assaults, which could lead to lifelong disease control. Nanomaterials have also arisen as clever carriers for drugs, enhancing their stability, availability, and effectiveness while reducing side effects. Together, these approaches point towards safer, more precise, and personalized treatments for autoimmune and immune-associated disorders [25, 26].

Potential Impact on AMR and ADRs

Integrative regimens may:

- Reduce antibiotic exposure.
- Slow resistance selection.
- Lower ADRs.
- Improve immune resilience.

DISCUSSION

Mechanistic Pathways

Potential mechanisms include:

- Synergistic antimicrobial action.
- Immune modulation (Th1/Th2/Th17 balance).
- Microbiome restoration.
- Reduced oxidative stress.
- Detoxification improving drug tolerance.

Challenges

- Need for phytochemical standardization.
- Regulatory harmonization.
- Herb-drug interaction monitoring.
- Multi-omics integration.
- Blinding in Panchakarma trials.

Opportunities

- Integrative AMR stewardship.
- Multi-omics monitoring.
- Personalized dosha-immune phenotype mapping.
- Global Ayurveda–biomedicine collaborations.

CONCLUSION

The convergence of AMR, autoimmune disease burden, and ADR challenges demands innovative, multi-modal solutions. Evidence from alternative therapeutics and Emerging Ayurvedic research supports the idea that integrative healthcare can work synergistically alongside evidence-based modern medicine. The diverse nature of Ayurvedic interventions – phytotherapy, Panchakarma procedures, diet, lifestyle modifications, constitution-based personalized care – offers a set of promising complementary approaches against complex challenges, including antimicrobial resistance (AMR) and autoimmune diseases. A rigorously standardized and evidence-driven integrative framework combining validated Ayurvedic therapies with modern diagnostics, microbiological monitoring, immunological assessments, and personalized treatment plans based on individuals' Prakriti profiles can be expected to help reduce unnecessary antibiotic exposure, alleviate the selective pressure driving resistance evolution, improve immune regulation, mitigate adverse drug reactions, and result in improved patient safety, wellbeing, and satisfaction. Well-designed randomized clinical trials and multi-center studies are urgently required to explore efficacy, safety, mechanisms of actions, and long-term clinical benefits of such integrative strategies against AMR and autoimmune disorders.

REFERENCES

1. Singha B, Singh V, Soni V. Alternative therapeutics to control antimicrobial resistance: A general perspective. *Front Drug Discov*. 2024;4:1385460. doi: [10.3389/fddsv.2024.1385460](https://doi.org/10.3389/fddsv.2024.1385460).
2. Song Y, Li J, Wu Y. Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. *Signal Transduct Target Ther*. 2024;9:263. doi: [10.1038/s41392-024-01952-8](https://doi.org/10.1038/s41392-024-01952-8).
3. Ribeiro da Cunha B, Fonseca LP, Calado CRC. Antibiotic discovery: Where have we come from, where do we go? *Antibiotics (Basel)*. 2019;8(2):45. doi: [10.3390/antibiotics8020045](https://doi.org/10.3390/antibiotics8020045).
4. Gajdacs M, Albericio F. Antibiotic resistance: From the bench to patients. *Antibiotics (Basel)*. 2019;8(3):129. doi: [10.3390/antibiotics8030129](https://doi.org/10.3390/antibiotics8030129).
5. Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats. *P T*. 2015;40(4):277–283.
6. Ventola CL. The antibiotic resistance crisis: Part 2: Management strategies and new agents. *P T*. 2015;40(5):344–352.
7. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *Lancet*. 2022;399(10325):629–655. doi: [10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0).
8. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. *Pathog Glob Health*. 2015;109(7):309–318. doi: [10.1179/2047773215Y.0000000030](https://doi.org/10.1179/2047773215Y.0000000030).
9. World Health Organization. Antimicrobial resistance: Global report on surveillance. Geneva: World Health Organization; 2014.
10. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving global targets for antimicrobial resistance. *Science*. 2016;353(6302):874–875. doi: [10.1126/science.aaf9286](https://doi.org/10.1126/science.aaf9286).
11. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: Past, present and future. *Curr Opin Microbiol*. 2019;51:72–80. doi: [10.1016/j.mib.2019.10.008](https://doi.org/10.1016/j.mib.2019.10.008).
12. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: A rundown of a global crisis. *Infect Drug Resist*. 2018;11:1645–1658. doi: [10.2147/IDR.S173867](https://doi.org/10.2147/IDR.S173867).
13. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: A new paradigm for antimicrobial therapy. *Nat Chem Biol*. 2007;3(9):541–548. doi: [10.1038/nchembio.2007.24](https://doi.org/10.1038/nchembio.2007.24).
14. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, et al. Alternatives to antibiotics—A pipeline portfolio review. *Lancet Infect Dis*. 2016;16(2):239–251. doi: [10.1016/S1473-3099\(15\)00466-1](https://doi.org/10.1016/S1473-3099(15)00466-1).
15. Katiyar SK. Emerging phytochemicals for the prevention and treatment of head and neck cancer. *Molecules*. 2016;21(12):1610. doi: [10.3390/molecules21121610](https://doi.org/10.3390/molecules21121610).
16. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: Lessons learned from clinical trials. *AAPS J*. 2013;15(1):195–218. doi: [10.1208/s12248-012-9432-8](https://doi.org/10.1208/s12248-012-9432-8).
17. Pan SY, Litscher G, Gao SH, Zhou SF, Yu ZL, Chen HQ, et al. Historical perspective of traditional indigenous medical practices: The current renaissance and conservation of herbal resources. *Evid Based Complement Alternat Med*. 2014;2014:525340. doi: [10.1155/2014/525340](https://doi.org/10.1155/2014/525340).

18. Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol.* 2014;4:177. doi: [10.3389/fphar.2013.00177](https://doi.org/10.3389/fphar.2013.00177).
19. Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: An ethical analysis. *Bull World Health Organ.* 2008;86(8):594–599. doi: [10.2471/BLT.07.042820](https://doi.org/10.2471/BLT.07.042820).
20. Williamson EM. Synergy and other interactions in phytomedicines. *Phytomedicine.* 2001;8(5):401–409. doi: [10.1078/0944-7113-00060](https://doi.org/10.1078/0944-7113-00060).
21. Mukherjee PK, Venkatesh P, Ponnusankar S. Ethnopharmacology and integrative medicine – Let the history tell the future. *J Ayurveda Integr Med.* 2010;1(2):100–109. doi: [10.4103/0975-9476.65073](https://doi.org/10.4103/0975-9476.65073).
22. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: A comparative overview. *Evid Based Complement Alternat Med.* 2005;2(4):465–473. doi: [10.1093/ecam/neh140](https://doi.org/10.1093/ecam/neh140).
23. Vyas MK, Reddy KS. Herbal medicine in primary healthcare: An overview of evidence-based applications. *J Ayurveda Integr Med.* 2012;3(2):57–64.
24. Sahoo N, Manchikanti P, Dey S. Herbal drugs: Standards and regulation. *Fitoterapia.* 2010;81(6):462–471. doi: [10.1016/j.fitote.2010.02.001](https://doi.org/10.1016/j.fitote.2010.02.001).
25. Mosihuzzaman M. Herbal medicine in healthcare-an overview. *Nat Prod Commun.* 2012;7(6):1934578X1200700628.
26. Bandaranayake WM. Quality control, screening, toxicity, and regulation of herbal drugs. In: *Modern phytomedicine: turning medicinal plants into drugs.* 2006. p. 25–57.